HCGExplore study findings
What hCG contributed in a trial of congenital gonadotropin deficiency
2 numbered sourcesSource years 2025, 2026
Peptide bonds connect amino acids into short chains called peptides. Larger molecules built from amino-acid chains can also act as hormones. Human chorionic gonadotropin, or hCG, is a glycoprotein made of two chains with sugars attached. It can stimulate the receptor for luteinizing hormone in the testes. A 2026 trial examined how different treatments containing hCG affected the appearance of sperm in adults with congenital hypogonadotropic hypogonadism. [1, 2]
In this condition, inadequate signaling from the hypothalamus or pituitary limits the hormones needed for normal testicular development and function. Luteinizing hormone ordinarily stimulates Leydig cells to make testosterone. Follicle-stimulating hormone (FSH) acts on a different set of cells that support sperm development. An hCG treatment can supply a signal at the luteinizing-hormone receptor. The 2026 study asked whether adding testosterone early to a regimen containing hCG and FSH changed the time or the treatment exposure needed to produce detectable sperm. [1, 2]
The investigators randomly assigned 45 men to one of three approaches. One group received hCG, FSH and testosterone. Another began hCG and FSH together. The third began with hCG alone and later added FSH. The study was open-label, so participants and clinicians knew the assigned approach. The investigators reported that the group receiving all three reached sperm production with a lower median amount of hCG than the other groups. The proportions with detectable sperm and the time to detection did not differ clearly in the three-way comparison. [1]
These measurements describe different outcomes. The presence of sperm establishes that sperm production occurred at a level the test could detect. It does not establish a person's chance of becoming a parent, which depends on additional biological and clinical factors. A small trial can also miss important differences. The finding that the time to sperm detection was similar in this trial does not establish that all three strategies are equivalent across patients or outcomes. [1]
The U.S. label for Pregnyl includes selected cases of male hypogonadotropic hypogonadism. The trial concerned a particular congenital diagnosis and compared specific multi-hormone approaches. Its results do not establish the same effects in people whose testes are unable to respond, or in other causes of low testosterone or infertility. The trial gives recent human data on a defined cause of impaired gonadotropin signaling and describes how the investigators measured the response. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
